PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q96509

François P. BISCHOFF, et al.

Appln. No.: Based on PCT/JP05/004266

Confirmation No.: Unknown Group Art Unit: Unknown

Filed: September 1, 2006 Examiner: Unknown

For: PYRROLOPYRIMIDINE DERIVATIVES

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

10/591765 IAP9 Rec'd PCT/PTO 01 SEP 2006

INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: Based on PCT/JP05/004266

Attorney Docket No.: Q96509

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement

under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for

foreign language documents, Applicant encloses herewith a copy of a Communication from a

foreign patent office in a counterpart application citing such documents (International Search

Report for PCT/JP05/004266 dated July 1, 2005), together with an English-language version (if

not already included) of at least that portion of the Communication indicating the degree of

relevance found by the foreign patent office.

The submission of the listed documents is not intended as an admission that any such

document constitutes prior art against the claims of the present application. Applicant does not

waive any right to take any action that would be appropriate to antedate or otherwise remove any

listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account.

Respectfully submitted,

Registration No. 30,951

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE 23373

CUSTOMER NUMBER

Date: September 1, 2006

IAP9 Rec'd PCT/PT94 ED PTO/SB/08 A & B (08-03)

Substitute for Form 1449 A & B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Comp	icio ij iliio iiii		
Application Number	Based on PCT/JP05/004266		
Confirmation Number	Unknown		
Filing Date	September 1, 2006		
First Named Inventor	Francois P. BISCHOFF		
Art Unit	Unknown		
Examiner Name	Unknown		
Attorney Docket Number	O96509		

U.S. PATENT DOCUMENTS					
F	Cite	Document		Publication Date MM-DD-YYYY	
Examiner Initials*	Cite No. ¹	Number	Kind Code ² (if known)		Name of Patentee or Applicant of Cited Documen
		US			
		UŠ			
		US			
		ÚS			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date	Name of Patentee or	
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation ⁶
		WO	94/13676	A1	06-23-1994	PFIZER INC.	
		wo	02/088095	Al	11-07-2002	GLAXO GROUP LIMITED Romano DE FABIO	
		wo	02/100863	A1	12-19-2002	GLAXO GROUP LIMITED	
		JP	2000-86663	A	03-28-2000	TAISHO PHARMA CO LTD	Abstract
		ЕР	0 976 745	Al	02-02-2000	TAISHO PHARMACEUTICAL CO. LTD	
		WO	2004/099209	Al	11-18-2004	F. HOFFMANN-LA-ROCHE AG	
			_		I		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazing Initials* No. 1 journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where publish		I. Translation	
			ļ <u>.</u>
			
. —	w. '		

· · · · · · · · · · · · · · · · · · ·		
Examiner Signature	Date	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.